Barclays raised the firm’s price target on Privia Health (PRVA) to $23 from $21 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for the managed care space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health enters Arizona in partnership with Integrated Medical Services
- Buy Rating for Privia Health Group: Stability and Growth Amid Medicare Model Changes
- Privia Health Group: Strong Execution and Growth Potential with Revised Price Target
- Privia Health price target raised to $29 from $26 at Citizens JMP
- Privia Health Group: Strong Financial Performance and Strategic Positioning Justify Buy Rating and Increased Price Target